QR Code

Sotrovimab retains activity against SARS-CoV-2 omicron variant BQ.1.1 in a non-human primate model

The SARS-CoV2 Omicron variants have acquired new Spike mutations leading to escape from the most of the currently available monoclonal antibody treatments reducing the options for patients suffering from severe Covid-19. Recently, both in vitro and in vivo data have suggested that Sotrovimab could r...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: Cécile Hérate, Romain Marlin, Franck Touret, Nathalie Dereuddre-Bosquet, Flora Donati, Francis Relouzat, Laura Junges, Mathilde Galhaut, Océane Dehan, Quentin Sconosciuti, Antoine Nougairède, Xavier de Lamballerie, Sylvie van der Werf, Roger Le Grand
Hōputu: Artigo
Reo:Inglês
I whakaputaina: Elsevier 2023-06-01
Rangatū:Heliyon
Ngā marau:
SARS-CoV2
Sotrovimab
Non human primate
BQ.1.1
Urunga tuihono:http://www.sciencedirect.com/science/article/pii/S2405844023038719
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite